title: [Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?].
abstract: The search for new risk markers of cardiovascular (CV) risk is continuous, aimed to improve its estimate. Among them, the measurement of C-reactive protein (CRP) levels seems the most promising one. CV risk evaluation systems as Reynolds score, integrating CPR dosage to classic risk factors, were shown to improve the detection of subjects at higher risk, who deserve a more effective CV prevention. The use of CRP as a guide in primary prevention was tested for the first time in the JUPITER study, a large randomized trial comparing rosuvastatin 20 mg and placebo. Admission criteria were based on the presence of an inflammatory status only (CRP >2 mg/l), aside from CV risk factors (LDL <130 mg/dl). Rosuvastatin 20 mg, compared to placebo, significantly reduced composite primary endpoint (CV mortality, myocardial infarction, ischemic stroke, hospitalization for unstable angina and myocardial revascularization). These results confirmed the continuous relationship between decreased cholesterol level and clinical benefit also in primary prevention. The high prevalence of metabolic syndrome in this study population confirmed the link between this condition and the presence of an inflammatory status, and the high incidence of events occurred in the placebo group suggests an important role of CRP in the detection of subjects at higher CV risk. The greatest reduction of CV events was seen in the subgroup of patient who achieved the "double target" of both decreased lipids and inflammation marker, similarly to PROVE IT-TIMI 22 in secondary prevention. The presence of an inflammatory status may allow the detection of more vulnerable patients, where statin treatment may result in a greater benefit, as both LDL cholesterol and inflammatory status are reduced, and clinical CV events are consequently decreased.
authors.affiliation: Dipartimento di Medicina Interna, Scienze Cardiovascolari ed Immunologiche, Università degli Studi Federico II, Napoli. fpperron@unina.it
authors.forename: Pasquale Perrone
authors.initials: PP
authors.lastname: Filardi
authors.forename: Milena
authors.initials: M
authors.lastname: Cecere
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Savarese
authors.forename: Carmen
authors.initials: C
authors.lastname: Damore
authors.forename: Antonio
authors.initials: A
authors.lastname: Parente
authors.forename: Sirio
authors.initials: S
authors.lastname: Conte
authors.forename: Gloria
authors.initials: G
authors.lastname: Coutsoumbas
mesh_terms: D002097:C-Reactive Protein / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007249:Inflammation / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D002097:C-Reactive Protein; D002784:Cholesterol